Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Evaluate's commercial intelligence on the pharmaceutical, biotechnology, and medical device industries is consistently referenced by leading business and industry publications such as the Financial Times, Wall Street Journal, and Nature.
Download our latest Media Kit for a forward-looking view of top companies, products, and more to support your editorial content.
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
Vantage published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital…
Five of the top 10 drugs for Medicare Part B spending face biosimilar competition in the coming years — just as CMS has cleared the way for Medicare Advantage plans to…
The problem comes when reality catches up with the froth, as Australia’s Neuren Pharma found out last week, said EP Vantage, the editorial arm of the Evaluate…